Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Oct 30;10(10):CD009460.
doi: 10.1002/14651858.CD009460.pub2.

Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease

Anna L Sampson  1 , Richard F Singer, Giles D Walters
Affiliations
Meta-Analysis

Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease

Anna L Sampson et al. Cochrane Database Syst Rev. .

Abstract

Background: Non-randomised data have shown a link between hyperuricaemia and the progression or development of chronic kidney disease (CKD). If this is correct, urate lowering therapy might form an important part of chronic kidney disease care, reducing risks for cardiovascular outcomes and end-stage kidney disease.

Objectives: This review aims to study the benefits and harms of uric acid lowering therapy on the progression of CKD and other cardiovascular endpoints.

Search methods: We searched the Cochrane Kidney and Transplant Specialised Register to 20 July 2017 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.

Selection criteria: All randomised controlled trials testing primary urate lowering therapy in patients with or without CKD.

Data collection and analysis: Two authors independently assessed study quality and extracted data. Statistical analyses were performed using a random effects model and results expressed as risk ratio (RR) with 95% confidence intervals (CI) for dichotomous outcomes or mean difference (MD) for continuous outcomes, or standardised mean difference (SMD) if different scales were used.

Main results: Twelve studies (1187 participants) were included in the review. Risk of bias was unclear for the majority of domains in each study.Uric acid lowering therapy may make little or no difference in death at six months (2 studies, 498 participants: RR 1.66, 95% CI 0.61 to 4.48) or two years (2 studies, 220 participants): RR 0.13, 95% CI 0.02 to 1.06) (low certainty evidence). Uric acid lowering therapy may make little of no difference (low certainty evidence) in the incidence of ESKD at one or two years. Kidney function may be improved by uric acid lowering therapy at one year with a reduction in serum creatinine (2 studies, 83 participants: MD -73.35 µmol/L, 95% CI -107.28 to -39.41) and a rise in eGFR (1 study, 113 participants: MD 5.50 mL/min/1.73 m2, 95% CI 0.59 to 10.41). However it probably makes little or no difference to eGFR at two years (2 studies, 164 participants: MD 4.00 mL/min, 95% CI -3.28 to 11.28). Uric acid lowering therapy reduced uric acid levels at all time points (3, 4, 6, 12 and 24 months) (high certainty evidence).There is insufficient evidence to support an effect on blood pressure, proteinuria or other cardiovascular markers by uric acid lowering therapy. It should be noted that the apparent benefits of treatment were not apparent at all time points, introducing the potential for bias.

Authors' conclusions: There is limited data which suggests uric acid lowering therapy may prevent progression of chronic kidney disease but the conclusion is very uncertain. Benefits were not observed at all time points and study quality was generally low. Larger studies are required to study the effect of uric acid lowering therapy on CKD progression. Three ongoing studies will hopefully provide much needed high quality data.

PubMed Disclaimer

Conflict of interest statement

  1. Anna Sampson: none known

  2. Giles Walters: none known

  3. Richard Singer: none known

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 1 Dialysis.
1.2
1.2. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 2 Serum creatinine.
1.3
1.3. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 3 eGFR.
1.4
1.4. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 4 Death.
1.5
1.5. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 5 Systolic BP.
1.6
1.6. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 6 Diastolic BP.
1.7
1.7. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 7 Hospitalisation.
1.8
1.8. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 8 Adverse events.
1.9
1.9. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 9 C‐reactive protein.
1.10
1.10. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 10 Cardiovascular markers.
1.11
1.11. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 11 Proteinuria.
1.12
1.12. Analysis
Comparison 1 Uric acid lowering therapies (UAR) versus placebo/no treatment, Outcome 12 Uric acid.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD009460

References

References to studies included in this review

Bergamini 2010 {published data only}
    1. Bergamini C, Cicoira M, Rossi A, Cassater D, Zanolla L, Vassanelli C. Allopurinol lowers NT‐proBNP plasma levels and improves diastolic function in heart failure patients: A double‐blind, placebo‐controlled study [abstract no: P4847]. European Heart Journal 2010;31(Suppl 1):849. [EMBASE: 70282775]
Dogan 2011 {published data only}
    1. Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, et al. Effect of long‐term and high‐dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Pressure 2011;20(3):182‐7. [MEDLINE: ] - PubMed
Gibson 1980 {published data only}
    1. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases 1982;41(1):59‐65. [MEDLINE: ] - PMC - PubMed
    1. Gibson T, Simmonds HA, Potter C, Rogers V. A controlled study of the effect of long term allopurinol treatment on renal function in gout. Advances in Experimental Medicine & Biology 1980;122A:257‐62. [MEDLINE: ] - PubMed
Goicoechea 2010 {published data only}
    1. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, et al. Allopurinol and progression of CKD and cardiovascular events: long‐term follow‐up of a randomized clinical trial. American Journal of Kidney Diseases 2015;65(4):543‐9. [MEDLINE: ] - PubMed
    1. Goicoechea M, Vinuesa SG, Verdalles U, Ruiz‐Caro C, Ampuero J, Rincón A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clinical Journal of The American Society of Nephrology: CJASN 2010;5(8):1388‐93. [MEDLINE: ] - PMC - PubMed
Kanbay 2011 {published data only}
    1. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.[Erratum appears in Clin J Am Soc Nephrol. 2011 Dec;6(12):2901‐2]. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(8):1887‐94. [MEDLINE: ] - PMC - PubMed
Momeni 2010 {published data only}
    1. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Allopourinol effect on reducing proteinuria in diabetic retinopathy. Journal of Isfahan Medical School 2010;28(107):271‐8. [EMBASE: 359535811]
    1. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iranian Journal of Kidney Diseases 2010;4(2):128‐32. [MEDLINE: ] - PubMed
OPT‐CHF Study 2004 {published data only}
    1. Freudenberger RS, Schwarz RP Jr, Brown J, Moore A, Mann D, Givertz MM, et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III ‐ IV congestive heart failure. Expert Opinion on Investigational Drugs 2004;13(11):1509‐16. [MEDLINE: ] - PubMed
    1. George J, Struthers A. The OPT‐CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose. Journal of the American College of Cardiology 2009;53(25):2405. [MEDLINE: ] - PubMed
    1. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT‐CHF study. Journal of the American College of Cardiology 2008;51(24):2301‐9. [MEDLINE: ] - PubMed
Sarris 2007 {published data only}
    1. Sarris E, Bagiatudi G, Stavrianaki D, Salpigidis K, Siakotos M. Use of allopurinol in slowing the progression of chronic renal disease [abstract no: FP128]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi61.
Shi 2012 {published data only}
    1. Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney & Blood Pressure Research 2012;35(3):153‐60. [MEDLINE: ] - PMC - PubMed
Sircar 2015 {published data only}
    1. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6‐month, double‐blind, randomized, placebo‐controlled trial. American Journal of Kidney Diseases 2015;66(6):945‐50. [MEDLINE: ] - PubMed
Siu 2006 {published data only}
    1. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. American Journal of Kidney Diseases 2006;47(1):51‐9. [MEDLINE: ] - PubMed
Tuta 2006 {published data only}
    1. Tuta L, Sburian A, Voinea F. Early allopurinol therapy slows progression of renal disease in predialysis patients with hyperuricemia [abstract no: MP261]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv386.

References to studies excluded from this review

CONFIRMS Study 2012 {published data only}
    1. Becker MA, Macdonald PA, Hunt BJ, Jackson RL. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes, Obesity & Metabolism 2013;15(11):1049‐55. [MEDLINE: ] - PMC - PubMed
    1. Jackson RL, Hunt B, Macdonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients >/=65 years of age. BMC Geriatrics 2012;12:11. [MEDLINE: ] - PMC - PubMed
    1. Wells AF, MacDonald PA, Chefo S, Jackson RL. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskeletal Disorders 2012;13:15. [MEDLINE: ] - PMC - PubMed
NCT00174915 {published data only}
    1. NCT00174915. A phase 3, randomized, multicenter, allopurinol and placebo‐controlled study assessing the safety and efficacy of oral febuxostat in subjects with gout. clinicaltrials.gov/ct2/show/NCT00174915 (first received 9 September 2005).
NU‐FLASH Study 2013 {published data only}
    1. Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU‐FLASH Trial). Circulation Journal 2013;77(8):2043‐9. [MEDLINE: ] - PubMed
    1. Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU‐FLASH trial for CKD). Journal of Cardiology 2015;66(4):298‐303. [MEDLINE: ] - PubMed
Sundy 2011 {published data only}
    1. Baraf HS, Becker MA, Gutierrez‐Urena SR, Treadwell EL, Vazquez‐Mellado J, Rehrig CD, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open‐label extension in patients with chronic gout refractory to conventional therapy. Arthritis Research & Therapy 2013;15(5):R137. [MEDLINE: ] - PMC - PubMed
    1. Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Research & Therapy 2014;16(2):R60. [MEDLINE: ] - PMC - PubMed
    1. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez‐Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306(7):711‐20. [MEDLINE: ] - PubMed
    1. Sundy JS, Becker MS, Huang WY, Waltrip RW, Chandraker AK. Treatment failure gout: efficacy and safety of pegloticase in phase 3 trials [abstract no: 1471]. American Journal of Transplantation 2009;9(Suppl 2):600.
    1. Yood RA, Ottery FD, Irish W, Wolfson M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo‐controlled, phase 3 clinical trials. BMC Research Notes 2014;7:54. [MEDLINE: ] - PMC - PubMed
Tanaka 2015 {published data only}
    1. Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel‐group, randomized, controlled trial. Clinical & Experimental Nephrology 2015;19(6):1044‐53. [MEDLINE: ] - PubMed
Tausche 2014 {published data only}
    1. Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, et al. As compared to allopurinol, urate‐lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatology International 2014;34(1):101‐9. [MEDLINE: ] - PubMed
Whelton 2007 {published data only}
    1. Whelton A, MacDonald P, Lloyd E, Lademacher C. The long‐term stability of renal function in hyperuricemic subjects with gout treated with febuxostat [abstract no: SA‐PO918]. Journal of the American Society of Nephrology 2007;18(Abstracts):545A.
    1. Whelton A, MacDonald PA, Hunt BJ, Joseph‐Ridge N. Febuxostat, a novel non‐purine selective inhibitor of xanthine oxidase, in patients with a history of nephrolithiasis [abstract no: F‐PO894]. Journal of the American Society of Nephrology 2006;17(Abstracts):525A.

References to studies awaiting assessment

Hosoya 2014 {published data only}
    1. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clinical & Experimental Nephrology 2014;18(6):876‐84. [MEDLINE: ] - PMC - PubMed
Saag 2013 {published data only}
    1. Saag KG, Becker MA, Whelton A, MacDonald PA, Zhou Y, Gunawardhana L. Effect of febuxostat on serum urate levels in gout subjects with hyperuricemia and moderate‐to‐severe renal impairment: A randomized controlled trial [abstract no: 1178]. Arthritis & Rheumatism 2013;65(Suppl 10):S498‐9. [EMBASE: 71318653]
Tani 2015 {published data only}
    1. Tani S, Nagao K, Hirayama A. Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open‐label, pilot study. Clinical Drug Investigation 2015;35(12):823‐31. [MEDLINE: ] - PubMed
    1. Tani S, Nagao K, Hirayama A. Febuxostat, a xanthine oxidase inhibitor, may improve cardiorenal interaction: a randomized controlled pilot study [abstract]. European Heart Journal 2014;35(Suppl 1):904‐5. [EMBASE: 71650121]
    1. Tani S, Takahashi A, Nagao K, Hirayama A. Febuxostat ‐ a xanthine oxidase inhibitor ‐ may improve cardiorenal interaction: a randomized controlled pilot study [abstract]. Circulation 2014;130(Suppl 2):A9432. [EMBASE: 71712984]
Tuta 2014 {published data only}
    1. Tuta L, Stanigut A. Allopurinol therapy for hyperuricemia reduces inflammation and progression of renal disease in moderate chronic kidney disease [abstract no: SP148]. Nephrology Dialysis Transplantation 2014;29(Suppl 3). [EMBASE: 71491775]

References to ongoing studies

CKD‐FIX Study 2011 {published data only}
    1. The CKD‐FIX Trial: controlled trial of slowing of kidney disease progression from the inhibition of xanthine oxidase. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=343216 (first received 19 July 2011).
FEATHER Study 2014 {published data only}
    1. Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials [Electronic Resource] 2014;15(1):26. [MEDLINE: ] - PMC - PubMed
PERL Study 2013 {published data only}
    1. Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Current Diabetes Reports 2013;13(4):550‐9. [MEDLINE: ] - PMC - PubMed

Additional references

Bellomo 2010
    1. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. American Journal of Kidney Diseases 2010;56(2):264‐72. [MEDLINE: ] - PubMed
Bose 2013
    1. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A. Effects of uric acid‐lowering therapy on renal outcomes: a systematic review and meta‐analysis. Nephrology Dialysis Transplantation 2014;29(2):406‐13. [MEDLINE: ] - PubMed
Cameron 2005
    1. Cameron JS, Simmonds HA. Uric acid and the kidney. Oxford Textbook of Clinical Nephrology. 3rd Edition. Vol. 2, Oxford University Press, 2005:1059‐73.
Coresh 2007
    1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038‐47. [MEDLINE: ] - PubMed
Daskalopoulou 2005
    1. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Current Pharmaceutical Design 2005;11(32):4161‐75. [MEDLINE: ] - PubMed
Feig 2008
    1. Feig DI, Kang D, Johnson RJ. Uric acid and cardiovascular risk. New England Journal of Medicine 2008;359(17):1811‐21. [MEDLINE: ] - PMC - PubMed
GRADE 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. [MEDLINE: ] - PMC - PubMed
Hall 1967
    1. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long‐term population study. American Journal of Medicine 1967;42(1):27‐37. [MEDLINE: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: ] - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S [editors]. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Kang 2002
    1. Kang D, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A role for uric acid in the progression of renal disease. Journal of the American Society of Nephrology 2002;13(12):2888‐97. [MEDLINE: ] - PubMed
Kosugi 2009
    1. Kosugi T, Nakayama T, Heinig M, Zhang L, Yuzawa Y, Sanchez‐Lozada LG, et al. Effect of lowering uric acid on renal disease in type 2 diabetic db/db mice. American Journal of Physiology ‐ Renal Physiology 2009;297(2):F481‐8. [MEDLINE: ] - PMC - PubMed
Levey 2012
    1. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379(9811):165‐80. [MEDLINE: ] - PubMed
Lin 2000
    1. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin‐Hu, Kinmen. Journal of Rheumatology 2000;27(4):1045‐50. [MEDLINE: ] - PubMed
Matsushita 2010
    1. Chronic Kidney Disease Prognosis Consortium, Matsushita K, Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all‐cause and cardiovascular mortality in general population cohorts: a collaborative meta‐analysis. Lancet 2010;375(9731):2073‐81. [MEDLINE: ] - PMC - PubMed
Nakagawa 2006
    1. Nakagawa T, Mazzali M, Kang DH, Sanchez‐Lozada LG, Herrera‐Acosta J, Johnson RJ. Uric acid ‐ A uremic toxin?. Blood Purification 2006;24(1):67‐70. [MEDLINE: ] - PubMed
Schünemann 2011a
    1. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Schünemann 2011b
    1. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Uaratanawong 2011
    1. Uaratanawong S, Suraamornkul S, Angkeaw S, Uaratanawong R. Prevalence of hyperuricemia in Bangkok population. Clinical Rheumatology 2011;30(7):887‐93. [MEDLINE: ] - PubMed
Winearls 2010
    1. Winearls CG, Haynes R, Glassock R. CKD staging ‐ evolution not revolution. Nefrologia 2010;30(5):493‐500. [MEDLINE: ] - PubMed

Publication types

MeSH terms